CJC-1295 + Ipamorelin Side Effects: 48 Skin-Term Mentions, No AE Table
48 of 2,113 question posts matched the broad cjc-ipa regex and a redness/welt/hive/itch term within 250 characters. These are mentions, not reaction rates.
The headline counts mentions (corpus 12 months). “No AE Table” describes retrieved sources: the ipamorelin abstract prints a composite percentage pair (search log, 2026-09-13).
The listed CJC-1295 form is modified GRF(1-29), without DAC (Product API, labeled composition). Ipamorelin is a synthetic pentapeptide (product API, labeled composition).
The blend label states: “The 10 mg item is co-lyophilized in a single vial at a fixed 5 mg plus 5 mg composition.” (Product API, labeled composition). For CJC-1295/Ipamorelin, it adds: “The 20 mg item is two separately sealed single-peptide vials, 10 mg CJC-1295 no-DAC and 10 mg ipamorelin.” (Product API, labeled composition).
This report separates corpus questions, human measurements, animal experiments and agency statements.
CJC-1295 and ipamorelin are listed at PeptidesDirect as research-grade peptides.
CJC-1295 without DAC (Mod GRF 1-29) is a synthetic 29-amino-acid GHRH(1-29) analog and GHRH receptor agonist. Research-grade lyophilized powder, specified purity at or above 99% (HPLC), batch-specific CoA. Laboratory use only.
Ipamorelin is a synthetic pentapeptide and a selective agonist at the GHS-R1a (ghrelin) receptor on pituitary somatotrophs. Research-grade lyophilized powder, specified purity at or above 98% (HPLC), batch CoA.
What research communities ask about
The Reddit “12 months” window is labeled 2025-08-01 to 2026-09-04, with 2,113 compound-matching question posts (corpus 12 months). The separate delta covers 2026-09-04 to 2026-09-12, with 74 matching posts (corpus delta). Longer-window dates are fixed script labels; delta dates use UTC timestamps. Different subreddit sets preclude pooling or trend comparisons.
Method: title plus body is matched case-insensitively using regex label cjc-ipa:
\bcjc[- ]?1295\b|\bcjc\b|\bipamorelin\b|\bipa\b(?!\s*(beer|ale))|\bmod[- ]?grf\b
Deduplication retains the first post ID occurrence; delta excludes previously seen IDs. A category-match start must lie within 250 characters of a compound-match start (corpus method). These are counts of question posts mentioning terms, not rates; the bare token “ipa” broadens the denominator, because the regex excludes it only when “beer” or “ale” follows. Matches include questions, reports and denials; causality is not assessed.
Cells mean “N of M question posts mention cjc-ipa and the category term within 250 characters” (corpus method). Column sources are corpus 12 months and corpus delta, respectively.
- 12 months
- 34 of 2,113
- Delta
- 1 of 74
- Meaning
- Stinging, burning
- 12 months
- 48 of 2,113
- Delta
- 4 of 74
- Meaning
- Red marks, rash, wheals
- 12 months
- 21 of 2,113
- Delta
- 2 of 74
- Meaning
- Knots, hard spots
- 12 months
- 4 of 2,113
- Delta
- 0 of 74
- Meaning
- Bruising
- 12 months
- 17 of 2,113
- Delta
- 2 of 74
- Meaning
- Swollen, edema
- 12 months
- 15 of 2,113
- Delta
- 0 of 74
- Meaning
- Sore, painful, hurts
- 12 months
- 9 of 2,113
- Delta
- 0 of 74
- Meaning
- Headache, migraine
- 12 months
- 25 of 2,113
- Delta
- 1 of 74
- Meaning
- Tiredness, lethargy
- 12 months
- 7 of 2,113
- Delta
- 1 of 74
- Meaning
- Nausea, vomiting
- 12 months
- 12 of 2,113
- Delta
- 0 of 74
- Meaning
- Lightheadedness, blood pressure
- 12 months
- 2 of 2,113
- Delta
- 0 of 74
- Meaning
- Hair-loss terms
- 12 months
- 3 of 2,113
- Delta
- 0 of 74
- Meaning
- Sleeplessness, drowsiness
- 12 months
- 0 of 2,113
- Delta
- 0 of 74
- Meaning
- Copper terms or “toxic”
- 12 months
- 5 of 2,113
- Delta
- 0 of 74
- Meaning
- Zinc
- 12 months
- 27 of 2,113
- Delta
- 0 of 74
- Meaning
- Bloating, puffiness
- 12 months
- 3 of 2,113
- Delta
- 0 of 74
- Meaning
- Infection terms
- 12 months
- 35 of 2,113
- Delta
- 5 of 74
- Meaning
- Allergic terminology
Column sources: corpus 12 months; corpus delta. Redness/welt/hive/itch, allergy/anaphylaxis and sting/burn lead the longer window (corpus 12 months). Copper/zinc categories are lexical matches.
The human record of CJC-1295
The doses named here are the arms of the cited studies, not an application protocol for research vials.
The randomized, double-blind, placebo-controlled trials of subcutaneous CJC-1295 with DAC lasted 28 and 49 days in healthy adults; the retrieved abstract prints neither total nor per-arm enrollment (PMID 16352683). Arms comprised single ascending doses or two or three weekly or biweekly doses; the abstract's concluding tolerability sentence refers to the subcutaneous CJC-1295 with DAC arms at 30 or 60 microg/kg and prints no event counts, no n and no denominator (PMID 16352683). “No serious adverse reactions were reported.” (PMID 16352683). That supplies no nonserious-event counts.
After a single subcutaneous CJC-1295 with DAC injection, mean plasma IGF-I was reported as 1.5- to 3-fold above baseline for 9 to 11 days; the abstract does not assign those measurements to individual dose arms (PMID 16352683).
In the open, before/after study of healthy men, subcutaneous CJC-1295 with DAC arms were 60 or 90 microg/kg once; IGF-I was +45% versus baseline, P < 0.001, during a 12-hour overnight profile sampled every 20 minutes one week later (PMID 17018654). Its abstract contains no adverse-event sentence (PMID 17018654). The proteomic paper analyzes an overlapping subset of 11 men given a single subcutaneous CJC-1295 with DAC dose of “60-90 μg/kg”; its full text contains no adverse-event section (PMID 19386527).
The terminated phase 2 CJC-1295 with DAC registry record enrolled 120 HIV-infected adults; route is unstated, arms are low dose, high dose and placebo, with 12 weeks of treatment plus 6 weeks of follow-up (NCT00267527, no posted results). It supplies no termination reason or adverse-event module (NCT00267527, no posted results).
The human record of ipamorelin
The randomized, double-blind postoperative-ileus phase 2 trial studied intravenous ipamorelin in adults after small or large bowel resection: 117 enrolled, with 114 in the combined safety population, not per arm (PMID 25331030). Any treatment-emergent adverse event was reported in 87.5% of the intravenous ipamorelin arm versus 94.8% of intravenous placebo; per-arm denominators are not printed (PMID 25331030). The intravenous ipamorelin arm was 0.03 mg/kg twice daily, versus intravenous placebo twice daily, from postoperative day 1 to 7 or discharge; this is the dosing window, while the abstract does not specify the adverse-event ascertainment window (PMID 25331030). The registry supplies no additional event table (NCT00672074, no posted results).
A healthy-male study used single intravenous ipamorelin infusions over 15 minutes, with 8 subjects per level: 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg (PMID 10496658). Across those intravenous ipamorelin levels, modeling reported a GH peak at 0.67 h, maximal production rate 694 mIU/L/h and SC50 214 nmol/L; its abstract prints no adverse-event sentence (PMID 10496658).
The completed intravenous ipamorelin dose-finding record enrolled 320 bowel-resection patients; results remain unpublished in this retrieval (NCT01280344, no posted results). Every retrieved human ipamorelin study used intravenous exposure; every retrieved human CJC-1295 publication used subcutaneous CJC-1295 with DAC (search log, 2026-09-13). The listed no-DAC blend is a different exposure.
The FDA bulk-substance rows
FDA's page “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” prints the following withdrawn-nomination row:
“Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.” (FDA bulk drug substances safety-risks page, fda.gov).
FDA does not distinguish DAC status in this row. Its ipamorelin acetate category 2 entry is dated September 29, 2023 (FDA bulk drug substances safety-risks page, fda.gov):
“A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility. FDA has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes.” (FDA bulk drug substances safety-risks page, fda.gov).
“Compounded drugs containing Ipamorelin acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Ipamorelin acetate also contains unnatural amino acids, which add to the complexity of peptide characterization.” (FDA bulk drug substances safety-risks page, fda.gov).
These are agency statements, not rates. FDA supplies no denominator, window or underlying study identification.
Selectivity questions: hormones, glucose and hunger
In conscious swine, ipamorelin produced no ACTH or cortisol release significantly different from GHRH stimulation even above 200-fold the GH ED50; route and exposure duration are unstated in the abstract (PMID 9849822). Swine plasma prolactin was unaffected in that experiment; route is unstated (PMID 9849822). The PubMed search ipamorelin[tiab] AND (cortisol[tiab] OR prolactin[tiab] OR ACTH[tiab]) returned 3 hits, but no human cortisol, prolactin or ACTH measurement under ipamorelin in the screened results (search log, 2026-09-13).
Normal and streptozotocin-diabetic rat pancreatic fragments incubated with ipamorelin at 10^-12 to 10^-6 M, with incubation duration not printed in the abstract, showed increased insulin secretion, p < 0.04; the abstract names no control incubation (PMID 15665799). This ex vivo measurement is not human blood glucose.
GH-intact mice receiving subcutaneous ipamorelin twice daily had increased food intake and serum leptin after 2 weeks (PMID 11162489). Mouse food intake is not human hunger. The rat pancreatic-fragment and mouse experiments report preclinical endpoints, not human glucose, insulin or appetite measurements (PMID 15665799; PMID 11162489).
IGF-1 and the growth question
The IGF-I measurements concern subcutaneous CJC-1295 with DAC (PMID 16352683; PMID 17018654). They do not measure a neoplasm outcome.
In GHRH-knockout mice, CJC-1295 with DAC at 2 microg at each injection for 5 weeks, every 24, 48 or 72 h, increased pituitary RNA and GH mRNA, with somatotroph proliferation versus placebo confirmed by immunohistochemistry; route is unstated in the abstract (PMID 16822960). This missing-signal mouse model is not an excess-signal experiment or a tumor finding (PMID 16822960). The reported mouse endpoints were pituitary RNA, GH mRNA and somatotroph proliferation (PMID 16822960). The GHRH-receptor question discusses receptor identity separately.
Preclinical tolerability observations
Pharmacology observations are not dedicated toxicology testing.
- Species
- Adult female rats
- Route
- Subcutaneous, three times daily
- Dose and duration as printed
- 0, 18, 90 or 450 microg/day for 15 days
- Observation
- Total IGF-I, IGFBPs and serum bone markers unchanged versus vehicle
- Source
- PMID 10373343
- Species
- Female rats
- Route
- Subcutaneous
- Dose and duration as printed
- Alone arm: 100 microg/kg three times daily for 3 months
- Observation
- Abstract prints no adverse observation or mortality
- Source
- PMID 11735244
- Species
- Young female rats
- Route
- In vivo route unstated
- Dose and duration as printed
- 21 days; dose unstated
- Observation
- Somatotroph ultrastructure unchanged; secretion-granule density increased, P < 0.05; somatotroph fraction unchanged only in 3-day basal cultures
- Source
- PMID 12168778
- Species
- Cisplatin-exposed ferrets
- Route
- Intraperitoneal, every 24 h
- Dose and duration as printed
- 1-3 mg/kg
- Observation
- No effect on acute (0-24 h) or delayed (24-72 h) emesis versus vehicle
- Source
- PMID 39043357
- Species
- GH-deficient and GH-intact mice
- Route
- Subcutaneous, twice daily
- Dose and duration as printed
- Up to 9 weeks; dose unstated
- Observation
- Food-intake findings described above concern GH-intact mice
- Source
- PMID 11162489
- Species
- Normal and diabetic rat pancreatic fragments
- Route
- In vitro incubation
- Dose and duration as printed
- 10^-12 to 10^-6 M; duration unstated
- Observation
- Insulin secretion increased, p < 0.04; control incubation unnamed
- Source
- PMID 15665799
- Species
- Conscious swine
- Route
- Unstated in abstract
- Dose and duration as printed
- More than 200-fold GH ED50 (2.3+/-0.03 nmol/kg); duration unstated
- Observation
- ACTH/cortisol findings described above
- Source
- PMID 9849822
- Species
- Male Sprague Dawley rats
- Route
- Subcutaneous
- Dose and duration as printed
- Single dose; quantity unstated
- Observation
- Plasma presence beyond 72 h; pharmacokinetics, not a toxicology endpoint
- Source
- PMID 15817669
- Species
- GHRH-knockout mice
- Route
- Injection; route unstated
- Dose and duration as printed
- 2 microg at each injection for 5 weeks, every 24, 48 or 72 h
- Observation
- Somatotroph proliferation versus placebo
- Source
- PMID 16822960
PeptidesDirect does not sell cisplatin.
Reactions asked about, mapped to sources
The retrieved sources print no per-term number for injection-site reactions, headache, water retention, fatigue or tingling; the ipamorelin percentage pair is a composite endpoint (PMID 25331030; search log, 2026-09-13). For injection-site reactions the logged searches are PubMed CJC-1295[tiab] OR "CJC 1295"[tiab], 33 hits; PubMed ipamorelin[tiab], 50 hits; PubMed ipamorelin[tiab] AND (subcutaneous[tiab] OR subcutaneously[tiab]) AND (humans[mh] OR volunteers[tiab] OR patients[tiab]), 0 hits; and ClinicalTrials.gov ipamorelin subcutaneous, 0 records (search log, 2026-09-13). Subcutaneous CJC-1295 with DAC abstracts omit injection-site data; full texts were inaccessible (PMID 16352683; PMID 17018654).
For flushing or warmth, the nearest retrieved wording is FDA's systemic vasodilatory reaction statement; hypersensitivity questions map to its immunogenicity warnings, neither a symptom rate nor a confirmed allergy count (FDA bulk drug substances safety-risks page, fda.gov). The logged flushing search, PubMed ("CJC-1295"[tiab] OR "CJC 1295"[tiab]) AND (toxicity[tiab] OR toxicology[tiab] OR "adverse event"[tiab] OR "adverse events"[tiab] OR "case report"[tiab]), returned 0 hits (search log, 2026-09-13). Corpus labels cannot fill these missing rows.
What the logged searches did not retrieve
These statements describe the logged searches, not the entire literature.
As of 2026-09-13, no human study of CJC-1295 without DAC (modified GRF 1-29) with safety or adverse-event reporting was retrieved (PubMed search: "modified GRF(1-29)"[tiab] OR "mod GRF 1-29"[tiab] OR "CJC-1295 without DAC"[tiab], 1 hit, an analytical paper on seized doping material and not a human study; ClinicalTrials.gov search: "modified GRF(1-29)", 0 records).
As of 2026-09-13, no dedicated toxicology study of ipamorelin was retrieved (PubMed search: ipamorelin[tiab] AND (toxicity[tiab] OR toxicology[tiab] OR genotoxicity[tiab]), 0 hits; ClinicalTrials.gov search: ipamorelin toxicology, 0 records).
As of 2026-09-13, no toxicology study, adverse-event analysis or case report on CJC-1295 was retrieved (PubMed search: ("CJC-1295"[tiab] OR "CJC 1295"[tiab]) AND (toxicity[tiab] OR toxicology[tiab] OR "adverse event"[tiab] OR "adverse events"[tiab] OR "case report"[tiab]), 0 hits; ClinicalTrials.gov search: "CJC-1295" adverse events, 0 records).
As of 2026-09-13, no case report and no pharmacovigilance or FAERS analysis of CJC-1295 or ipamorelin adverse events was retrieved (PubMed search: ("CJC-1295"[tiab] OR "CJC 1295"[tiab] OR ipamorelin[tiab]) AND (Case Reports[pt] OR pharmacovigilance[tiab] OR FAERS[tiab]), 0 hits; ClinicalTrials.gov search: ipamorelin adverse events, 2 records, both without posted results).
As of 2026-09-13, no human study of subcutaneous ipamorelin was retrieved (PubMed search: ipamorelin[tiab] AND (subcutaneous[tiab] OR subcutaneously[tiab]) AND (humans[mh] OR volunteers[tiab] OR patients[tiab]), 0 hits; ClinicalTrials.gov search: ipamorelin subcutaneous, 0 records). All retrieved human ipamorelin exposure is intravenous.
Who the human studies enrolled
- Molecule and route
- CJC-1295 with DAC, subcutaneous
- Arms
- Single ascending; repeated weekly/biweekly; placebo
- Duration
- 28 and 49 days
- Source
- PMID 16352683
- Molecule and route
- CJC-1295 with DAC, subcutaneous
- Arms
- 60 or 90 microg/kg once
- Duration
- Overnight profile one week later
- Source
- PMID 17018654
- Molecule and route
- CJC-1295 with DAC, subcutaneous
- Arms
- “60-90 μg/kg” once
- Duration
- Single injection
- Source
- PMID 19386527
- Molecule and route
- CJC-1295 with DAC; route unstated
- Arms
- Low dose; high dose; placebo
- Duration
- 12 weeks plus 6 weeks follow-up
- Source
- NCT00267527, no posted results
- Molecule and route
- Ipamorelin, intravenous
- Arms
- 4.21; 14.02; 42.13; 84.27; 140.45 nmol/kg
- Duration
- Single 15-minute infusion; follow-up unstated
- Source
- PMID 10496658
- Molecule and route
- Ipamorelin, intravenous
- Arms
- 0.03 mg/kg twice daily; placebo
- Duration
- Postoperative day 1 to 7 or discharge
- Source
- PMID 25331030; NCT00672074, no posted results
- Molecule and route
- Ipamorelin, intravenous
- Arms
- 0.03 mg/kg twice daily; 0.06 mg/kg twice daily; 0.06 mg/kg three times daily; matching placebo three times daily
- Duration
- Primary outcome “Up to 10 days”; AE outcome “14 day outpatient follow-up visit”
- Source
- NCT01280344, no posted results
Conclusions for Research
Corpus counts describe questions and terminology. Human findings remain specific to molecular form, route, population and measurement window. FDA statements identify concerns without quantifying incidence. The documented retrieval gaps prevent a symptom-by-symptom risk profile for the listed blend.
Sources and further reading:
- CJC-1295 ascending-dose trials. PMID 16352683: https://pubmed.ncbi.nlm.nih.gov/16352683/
- Overnight profiles. PMID 17018654: https://pubmed.ncbi.nlm.nih.gov/17018654/
- Proteomic subset. PMID 19386527: https://pubmed.ncbi.nlm.nih.gov/19386527/
- Ipamorelin postoperative-ileus trial. PMID 25331030: https://pubmed.ncbi.nlm.nih.gov/25331030/
- Ipamorelin intravenous modeling. PMID 10496658: https://pubmed.ncbi.nlm.nih.gov/10496658/
- Swine hormones. PMID 9849822: https://pubmed.ncbi.nlm.nih.gov/9849822/
- Pancreatic incubation. PMID 15665799: https://pubmed.ncbi.nlm.nih.gov/15665799/
- Mouse food intake. PMID 11162489: https://pubmed.ncbi.nlm.nih.gov/11162489/
- CJC-1295 GHRH-knockout mice. PMID 16822960: https://pubmed.ncbi.nlm.nih.gov/16822960/
- Rat somatotroph observations. PMID 12168778: https://pubmed.ncbi.nlm.nih.gov/12168778/
- Rat ipamorelin experiment. PMID 10373343: https://pubmed.ncbi.nlm.nih.gov/10373343/
- Chronic rat ipamorelin experiment. PMID 11735244: https://pubmed.ncbi.nlm.nih.gov/11735244/
- Ferret emesis experiment. PMID 39043357: https://pubmed.ncbi.nlm.nih.gov/39043357/
- CJC-1295 rat pharmacokinetics. PMID 15817669: https://pubmed.ncbi.nlm.nih.gov/15817669/
- ClinicalTrials.gov, NCT00267527: https://clinicaltrials.gov/study/NCT00267527
- ClinicalTrials.gov, NCT00672074: https://clinicaltrials.gov/study/NCT00672074
- ClinicalTrials.gov, NCT01280344: https://clinicaltrials.gov/study/NCT01280344
- FDA bulk drug substances safety-risks page, fda.gov, content current 04/22/2026: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Labeled composition of the listed items: product API of PeptidesDirect, retrieved 2026-09-13, field translations[locale=en].description of cjc-1295-ipamorelin-mix.
- Search logs: absence searches dated 2026-09-13, strings and hit counts printed above.
- Reddit corpus: .scratch/reddit-corpus/question-posts.jsonl and .scratch/reddit-corpus/delta-question-posts.jsonl, 12 months, 2025-08-01 to 2026-09-04; .scratch/reddit-corpus/delta2/questions.json, delta, 2026-09-04 to 2026-09-12. Counts: .scratch/paketA/cjc-ipa/reddit-counts.json. Compound regex: \bcjc[- ]?1295\b|\bcjc\b|\bipamorelin\b|\bipa\b(?!\s*(beer|ale))|\bmod[- ]?grf\b; category regexes and 250-character rule: .scratch/paketA/count-reactions.py.
Frequently Asked Questions
Related Products
CJC-1295 without DAC (Mod GRF 1-29) is a synthetic 29-amino-acid GHRH(1-29) analog and GHRH receptor agonist. Research-grade lyophilized powder, specified purity at or above 99% (HPLC), batch-specific CoA. Laboratory use only.
Ipamorelin is a synthetic pentapeptide and a selective agonist at the GHS-R1a (ghrelin) receptor on pituitary somatotrophs. Research-grade lyophilized powder, specified purity at or above 98% (HPLC), batch CoA.
Research blend of CJC-1295 no-DAC (Modified GRF 1-29), a GHRH receptor agonist, and ipamorelin, a GHS-R1a agonist. 10 mg co-lyophilized vial or 20 mg as two sealed vials. Purity at or above 98% per component, batch CoA.
This article is for informational purposes only for scientific research.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include VAT, the rate depends on the destination country; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.